{"id":36203,"date":"2021-02-08T08:00:00","date_gmt":"2021-02-08T07:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/new-data-from-pivotal-phase-iii-checkmate-9er-trial-of-cabometyx-in-combination-with-opdivo-showed-significantly-improved-qol-benefits-and-sustained-superior-efficacy-versus-sunitinib-in\/"},"modified":"2024-07-23T13:35:50","modified_gmt":"2024-07-23T11:35:50","slug":"new-data-from-pivotal-phase-iii-checkmate-9er-trial-of-cabometyx-in-combination-with-opdivo-showed-significantly-improved-qol-benefits-and-sustained-superior-efficacy-versus-sunitinib-in","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/press-releases\/new-data-from-pivotal-phase-iii-checkmate-9er-trial-of-cabometyx-in-combination-with-opdivo-showed-significantly-improved-qol-benefits-and-sustained-superior-efficacy-versus-sunitinib-in\/","title":{"rendered":"New data from pivotal Phase III CheckMate -9ER trial of Cabometyx\u00ae in combination with Opdivo\u00ae showed significantly improved QoL benefits and sustained superior efficacy versus sunitinib in patients living with aRCC"},"content":{"rendered":"